PFE Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Pfizer Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.60 |
| 52 Week High | US$40.37 |
| 52 Week Low | US$25.20 |
| Beta | 0.59 |
| 1 Month Change | 12.72% |
| 3 Month Change | 7.44% |
| 1 Year Change | -23.38% |
| 3 Year Change | -23.95% |
| 5 Year Change | -29.05% |
| Change since IPO | 6,432.43% |
Recent News & Updates
Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs
May 21Pfizer's Bottom May Be Here - Its Rich Yield Is Tempting
May 12Pfizer: Ignore The Dead Cat Bounce
May 06Recent updates
Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs
May 21Pfizer's Bottom May Be Here - Its Rich Yield Is Tempting
May 12Pfizer: Ignore The Dead Cat Bounce
May 06Pfizer Inc.'s (NYSE:PFE) Price Is Out Of Tune With Revenues
May 03
Is 7%-Yielding Pfizer Stock A Buy On The Dip Before Q1?
Apr 29Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth
Apr 19Pfizer: The Market Is Wrong
Apr 11Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns
Mar 18Pfizer: A Strong Buy Trading Below A 10 P/E Ratio
Mar 08Pfizer: A Value Trap, Not A Bargain
Feb 28Pfizer: Turnaround Is Gaining Momentum
Feb 21Is Pfizer (NYSE:PFE) A Risky Investment?
Feb 21Pfizer Is A Great Investment Over The Next Decade; Buy
Feb 09Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market
Jan 31Shareholder Returns
| PFE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.7% | 0.5% | -0.2% |
| 1Y | -23.4% | 17.9% | 28.2% |
Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned 17.9% over the past year.
Return vs Market: PFE underperformed the US Market which returned 28.2% over the past year.
Price Volatility
| PFE volatility | |
|---|---|
| PFE Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PFE has not had significant price volatility in the past 3 months.
Volatility Over Time: PFE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1849 | 88,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.
Pfizer Inc. Fundamentals Summary
| PFE fundamental statistics | |
|---|---|
| Market cap | US$161.84b |
| Earnings (TTM) | -US$288.00m |
| Revenue (TTM) | US$54.89b |
3.1x
P/S Ratio-582.4x
P/E RatioIs PFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFE income statement (TTM) | |
|---|---|
| Revenue | US$54.89b |
| Cost of Revenue | US$22.28b |
| Gross Profit | US$32.61b |
| Other Expenses | US$32.90b |
| Earnings | -US$288.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.051 |
| Gross Margin | 59.41% |
| Net Profit Margin | -0.52% |
| Debt/Equity Ratio | 75.5% |
How did PFE perform over the long term?
See historical performance and comparison